Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Burning Rock BiotechBNR +1.47%61 Debt-to-Equity is 0.10 as of Mar. 2026, which is 100% above its 10-year median of 0.05. GuruFocus rates BNR with a GF Score™ of 61/100 and a GF Value™ of $7.46 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 183 Medical Diagnostics & Research companies, Burning Rock Biotech ranks better than 74.32% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Burning Rock Biotech's Debt-to-Equity or its related term are showing as below:
BNR'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.45 Med: 0.05 Max: 0.16
Current: 0.1
During the past 9 years, the highest Debt-to-Equity Ratio of Burning Rock Biotech was 0.16. The lowest was -0.45. And the median was 0.05.
BNR's Debt-to-Equity is ranked better than 74.32% of 183
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.31
vs BNR: 0.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Burning Rock Biotech Debt-to-Equity Related Terms
Burning Rock Biotech Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Burning Rock Biotech's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Burning Rock Biotech's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Burning Rock Biotech Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Burning Rock Biotech's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Burning Rock Biotech's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Burning Rock Biotech (BNR) has a Debt-to-Equity of 0.10 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Burning Rock Biotech and its competitors. This is 100% above median its historical median of 0.05. According to the industry distribution chart, Burning Rock Biotech ranks #47 out of 183 companies in the Medical Diagnostics & Research industry, placing it in the top 25.7%.
Is Burning Rock Biotech's Debt-to-Equity too high?
Burning Rock Biotech's current Debt-to-Equity of 0.10 is 100% above median its 10-year median of 0.05. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.31. Burning Rock Biotech's value of 0.10 is 67.7% below this industry median. Based on the distribution chart, Burning Rock Biotech ranks #47 out of 183 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Burning Rock Biotech has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Debt-to-Equity compare to XGN and PRPO?
According to the Medical Diagnostics & Research industry distribution chart, Burning Rock Biotech ranks #47 out of 183 companies for Debt-to-Equity. This puts Burning Rock Biotech in the upper half of its industry. The industry median Debt-to-Equity is 0.31. Burning Rock Biotech's value of 0.10 is 67.7% below this benchmark. While the company's 10-year median is 0.05 vs. the industry median of 0.31, Burning Rock Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.31, based on 183 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Burning Rock Biotech's current Debt-to-Equity of 0.10 is 67.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Burning Rock Biotech and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Burning Rock Biotech's current Debt-to-Equity is 0.10, which is 100% above median its own 10-year median of 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.46, compared to a current price of $9.11 — trading 22.1% above its estimated fair value. The current Debt-to-Equity is 0.10, which is 100% above median its 10-year median of 0.05 and 67.7% below the Medical Diagnostics & Research industry median of 0.31. Burning Rock Biotech's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Debt-to-Equity is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Burning Rock Biotech (BNR) Overvalued in 2026?
Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued.
The current stock price of $9.11 is trading 22.1% above its estimated GF Value™ of $7.46.
GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.
Key valuation signals for BNR:
Debt-to-Equity: 0.10 (100% above median its 10-year median of 0.05)
GF Value™: $7.46 vs. price of $9.11 (22.1% above fair value)
Industry Position: 67.7% below the Medical Diagnostics & Research median (#47 of 183)
No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
61GF Score
Get the complete analysis for BNR
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BNR has been successfully added to your 
